Diagnosis of remnant hyperlipidaemia

Curr Opin Lipidol. 2022 Aug 1;33(4):227-230. doi: 10.1097/MOL.0000000000000831.

Abstract

Purpose of review: In recent years, there has been interest for the development of simplified diagnosis algorithms of dysbetalipoproteinemia (DBL) in order to avoid the complex testing associated with the Fredrickson criteria (reference method). The purpose of this review is to present recent advances in the field of DBL with a focus on screening and diagnosis.

Recent findings: Recently, two different multi-step algorithms for the diagnosis of DBL have been published and their performance has been compared to the Fredrickson criteria. Furthermore, a recent large study demonstrated that only a minority (38%) of DBL patients are carriers of the E2/E2 genotype and that these individuals presented a more severe phenotype.

Summary: The current literature supports the fact that the DBL phenotype is more heterogeneous and complex than previously thought. Indeed, DBL patients can present with either mild or more severe phenotypes that can be distinguished as multifactorial remnant cholesterol disease and genetic apolipoprotein B deficiency. Measurement of apolipoprotein B as well as APOE gene testing are both essential elements in the diagnosis of DBL.

Publication types

  • Review

MeSH terms

  • Apolipoprotein B-100
  • Apolipoproteins B / genetics
  • Apolipoproteins E / genetics
  • Cholesterol
  • Genotype
  • Humans
  • Hyperlipidemias* / diagnosis
  • Hyperlipidemias* / genetics
  • Hyperlipoproteinemia Type III* / diagnosis
  • Hyperlipoproteinemia Type III* / genetics

Substances

  • APOB protein, human
  • ApoE protein, human
  • Apolipoprotein B-100
  • Apolipoproteins B
  • Apolipoproteins E
  • Cholesterol